NTT: CEOs See Major Opportunities in Emerging Technologies to Tackle Social Challenges
18.12.2020 07:18:00 EET | Business Wire | Press release
WSJ Intelligence undertook a new international CEO survey for global technology and business solution provider NTT (TOKYO:9432). The survey focused on the dire necessity for complex digital technologies that have made it possible for businesses and societies to keep functioning amid the Covid-19 global pandemic.
WSJ Intelligence's global survey included 352 CEOs of large corporations representing ten major industries, across fifteen countries. The CEOs surveyed were asked about their corporation's role in society, their social-impact strategies, the stakeholders involved, and how those strategies were affected by the pandemic. This survey also examined the CEOs' confidence in a range of new and emerging technologies, and how those innovations might help the world to tackle enormous social challenges, such as the global supply chain, the future of work and health and well-being.
Key Findings:
- 56% of respondents believe corporations generate value by earning profits in a sustainable way that includes minimizing harm to society;
- 80% of stakeholder-centric executives say they pursue parallel financial and community outcomes, and see social-impact strategies as essential to financial returns;
- Technology powers the tools and opportunities to tackle social issues, but can also disrupt social stability through the rapid spread of false or misleading information;
- Cybersecurity is the only technology that a majority of executives consider fully adequate for their social-impact strategy; however adoption of cybersecurity technologies is not fast enough or sufficiently complete yet
- High-performance communications networks, followed by cloud computing and advanced analytics, are identified by CEOs as promising technologies with which to address social issues.
As the world continues to combat Covid-19 and plan for recovery, digital technology and social-impact programs will help to create the "new normal." The recovery from Covid-19 presents every organization with the opportunity to think in new ways and accelerate digital transformation.
About This Research
This research was conducted in July/August 2020 among CEOs across 15 countries, who participated in an online survey that aimed to understand how they viewed their company's responsibility to contribute, visibly and substantively, to achieving societal goals. Globally, 352 CEOs at companies with more than US$500M in revenue (with 75 of U.S. respondents at companies with more than $1BN) participated in quantitative research across 10 industries. "Investor-centric" respondents were defined as those whose view of the corporation is strictly to create value for shareholders by earning profit. "Stakeholder-centric" respondents answered either: "To create value for all stakeholders by earning profits in a sustainable way, which includes minimizing the harm that the business causes to society" or "Contribute to solutions for the challenges confronting people and society as a means of earning profits and generating long-term stakeholder value", when asked for their view of the role of the corporation in global society today.
[Reference]
READ THE WHITE PAPER (PDF: 2MB)
About WSJ Intelligence
WSJ Intelligence conducts bespoke and secondary research for brands and client brands of The Wall Street Journal | Barron's Group. Through rigorous analysis, WSJ Intelligence provides insights that are relevant, timely, and reliable.
About NTT
NTT believes in contributing to society through our business operations. We help people, clients and communities move confidently into the digital future and shape a better world. Our services include digital business consulting, technology and managed services for cybersecurity, applications, workplace, cloud, data centers and networks. As a top-5 global technology and business solutions provider, our diverse team of over 300,000 people operates in 80+ countries and regions and delivers services to over 190 of them.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201217006234/en/
Contact information
Yuzo Aramaki
Associate Manager
Press Relations of NTT Corporation
Mail: ntt-cnr-ml@hco.ntt.co.jp
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 14:42:00 EEST | Press release
2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr
Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
